Get started

Disc Medicine, Inc. (United States)

Alternate names: Disc Medicine, Disc Medicine, Inc.
ROR: 00pccsa50
OpenAlex ID: I4405266992
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma
2021 · E. Josue Ruiz, Adan Pinto-Fernandez, et al. · eLife · 51
Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients.
2002 · Mason W Russell, Douglas C A Taylor, et al. · PubMed · 30
Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
2002 · Daniel M Huse, Gordon Cummins, et al. · PubMed · 29
Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs
2022 · Scott P. Henry, Cecilia Arfvidsson, et al. · Nucleic Acid Therapeutics · 24
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group
2023 · Wenkui Li, Faye Vazvaei‐Smith, et al. · Clinical Pharmacology & Therapeutics · 15
PDF
First‐in‐Human Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of DISC‐0974, an Anti‐Hemojuvelin Antibody, in Healthy Participants
2024 · Natasha Novikov, Akshay Buch, et al. · The Journal of Clinical Pharmacology · 14
PDF
A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
2024 · Naseema Gangat, James M. Foran, et al. · Blood · 11
PDF
Development and Content Validation of Novel Patient-Reported Outcome Measures to Assess Disease Severity and Change in Patients with Erythropoietic Protoporphyria: The EPP Impact Questionnaire (EPIQ)
2024 · Susan Mathias, Laurie Burke, et al. · Patient Related Outcome Measures · 10
PDF
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
2024 · Bin Fan, Ghassan K. Abou-Alfa, et al. · Cancer Chemotherapy and Pharmacology · 9
PDF
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies
2021 · Yue Chen, Nelamangala V. Nagaraja, et al. · Drug Metabolism and Disposition · 9
PDF
The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria
2025 · Sarah Ducamp, Min Wu, et al. · Journal of Clinical Investigation · 7
PDF
Bitopertin, a Selective Glycine Transporter 1 Inhibitor, Reduced Protoporphyrin IX (PPIX) Level and Improved Liver Fibrosis in a Mouse Model of Erythropoietic Protoporphyria (EPP)
2022 · Min Wu, Sarah Ducamp, et al. · Blood · 7
How can we interpret the zero tolerance for bacterial ring rot in certified seed potatoes
1957 · C. E. Logsdon, H. W. Poulsen, et al. · American Journal of Potato Research · 7
Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria
2023 · Susan D. Mathias, Laurie Burke, et al. · Journal of Patient-Reported Outcomes · 6
PDF
A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
2023 · Naseema Gangat, James M. Foran, et al. · Blood · 6
Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections
2019 · Srikanth Venkatraman · Topics in medicinal chemistry · 6
Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial
2025 · Amy K. Yeung, Herbert L. Bonkovsky, et al. · Journal of the American Academy of Dermatology · 4
Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria
2024 · Amy Dickey, Sioban Keel, et al. · Blood · 4
PDF
An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria
2026 · Gayle Ross, Peter Stewart, et al. · Clinical and Experimental Dermatology · 3
Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity
2025 · Thomas Pfeiffer, Lisa Murray, et al. · Transplantation and Cellular Therapy · 3
Restricting glycine uptake with bitopertin improves erythropoiesis in preclinical models of Diamond-Blackfan anemia
2025 · Raymond T. Doty, Adam D. Munday, et al. · Blood Red Cells & Iron · 3
The EPP LIGHT Study: A Survey Describing the Burden of Erythropoietic Protoporphyria and X-Linked Protoporphyria
2024 · Hetanshi Naik, Manisha Balwani, et al. · Blood · 3
Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6
2024 · Guowen Liu, Haley Howell, et al. · Blood · 3
PDF
Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT
2024 · Thomas Pfeiffer, Clare Zimmerman, et al. · Transplantation and Cellular Therapy · 3
P1498: Initial Data From the Beacon Trial: a Phase 2, Randomized, Open-label Trial of Bitopertin in Erythropoietic Protoporphyria
2023 · Gayle Ross, Peter Stewart, et al. · HemaSphere · 3
Works count: 87
Citation count: 831
Year
Topic
Type